Clinical Utility of Positron Emission Tomography Magnetic Resonance Imaging (PET-MRI) in Gastrointestinal Cancers.
Anatomic imaging utilizing both CT (computed tomography) and MRI (magnetic resonance imaging) limits the assessment of cancer metastases in lymph nodes and distant organs while functional imaging like PET (positron emission tomography) scan has its limitation in spatial resolution capacity. Hybrid imaging utilizing PET-CT and PET-MRI are novel imaging modalities that are changing the current landscape in cancer diagnosis, staging, and treatment response. MRI has shown to have higher sensitivity in soft tissue, head and neck pathology, and pelvic disease, as well as, detecting small metastases in the liver and bone compared to CT. Combining MRI with PET allows for detection of metastases that may have been missed with current imaging modalities. In this review, we will examine the clinical utility of FDG PET-MRI in the diagnosis and staging of gastrointestinal cancers with focus on esophageal, stomach, colorectal, and pancreatic cancers. We will also explore its role in treatment response and future directions associated with it.
Department of Radiology, Stony Brook University Medical Center, Stony Brook, NY 11794, USA. robert.matthews@stonybrookmedicine.edu.
Robert
R
Matthews
Department of Medicine, Stony Brook University Medical Center, Stony Brook, NY 11794, USA. minsig.choi@stonybrookmedicine.edu.
Minsig
M
Choi
PET-MRI; cancer; fluorodeoxyglucose; magnetic resonance imaging; positron emission tomography